



(51) International Patent Classification:

C07K 14/725 (2006.01) C12N 5/0783 (2010.01)

A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/064607

(22) International Filing Date:

11 December 2020 (11.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/946,888 11 December 2019 (11.12.2019) US

63/085,969 30 September 2020 (30.09.2020) US

(71) Applicant: **A2 BIOTHERAPEUTICS, INC.** [US/US];

30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).

(72) Inventors: **KAMB, Carl, Alexander**; c/o A2 Biotherapeutics,

Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).

HAMBURGER, Agnes, E.; c/o A2 Biotherapeutics,

Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).

DIANDRETH, Breanna; c/o A2 Biother-apeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US). **DARIS, Mark, E.**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US). **DESHMUKH, Kiran**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).(74) Agent: **CHRISTIANSEN, William, T.** et al.; Cooley LLP,

1299 Pennsylvania Ave., Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

(54) Title: LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR




FIG. 8

(57) **Abstract:** Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*